MEIS2 and pancreatic adenocarcinoma: Meis2 has a high expression profile in cholangiocarcinoma, glioblastoma, brain lower grade glioma, pancreatic adenocarcinoma, liver hepatocellular carcinoma, skin cutaneous melanoma, stomach adenocarcinoma, and thymoma.